Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etamsylate intravitreal injection for dry age-related macular degeneration
2017-003899-31Phase 3Active
- Sponsor
- Dobecure
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of etamsylate in age-related macular degeneration (AMD) (2 arms), sponsored by Dobecure. Started Apr 2018; status: active.
02
Drugs
etamsylate
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on 2017-003899-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003899-31.